UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000542
Receipt number R000000660
Scientific Title Feasibility study of percutaneus endoscopic gastrostomy with Direct IDEAL PEG for patients with active head and neck cancer and esophageal cancer.
Date of disclosure of the study information 2007/01/01
Last modified on 2006/12/09 15:39:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility study of percutaneus endoscopic gastrostomy with Direct IDEAL PEG for patients with active head and neck cancer and esophageal cancer.

Acronym

Feasibility study of Direct IDEAL PEG

Scientific Title

Feasibility study of percutaneus endoscopic gastrostomy with Direct IDEAL PEG for patients with active head and neck cancer and esophageal cancer.

Scientific Title:Acronym

Feasibility study of Direct IDEAL PEG

Region

Japan


Condition

Condition

patients with active head and neck cancer and esophageal cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Oto-rhino-laryngology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

feasibility of percutaneus endoscopic gastrostomy with Direct IDEAL PEG for patients with active head and neck cancer and esophageal cancer

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

completion rate of PEG

Key secondary outcomes

Incidence of adverse event
Incidence of severe adverse event


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

PEG

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients with active head and neck cancer and esophageal cancer
performance status:0,1,2
written informed concent
laboratory data within 2 weeks before entry
WBC > 2500/mm3
Platelet > 7.5x104/mm3
Creatinine>2.0 mg/dl
Total bilirubin>3.0 mg/dl
AST, ALT>within 5 times of limitation of our hospital

Key exclusion criteria

1. impossible of passage of endoscopy
2. exsisting of fistula
3. after gastrectomy
4. active infection
5. risk of GI bleeding
6. massive ascites
7. disapproval of withdraw of anti coaguration agent
8. addiction of steroids
9. severe heart disease and uncontrolled hypertention and diabete
10. terminal stage within 4 months prognosis
11. ineligible judged by doctor in charge

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Manabu Muto

Organization

National Cancer Center Hospital East

Division name

Division Digestive Endoscopy and GI Oncology

Zip code


Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Tomonori Yano

Organization

National Cancer Center Hospital East

Division name

Division Digestive Endoscopy and GI Oncology

Zip code


Address


TEL


Homepage URL


Email

toyano@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Olympus

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2006 Year 12 Month 06 Day

Date of IRB


Anticipated trial start date

2006 Year 12 Month 01 Day

Last follow-up date

2007 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2006 Year 12 Month 08 Day

Last modified on

2006 Year 12 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000660


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name